QSS
ACRS icon

Quantitative Systematic Strategies’s Aclaris Therapeutics ACRS Stock Holding History

Quantitative Systematic Strategies’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,658
Closed -$240K – 11
2021
Q2 		$240K Sell
13,658
-4,513
-25% -$103K 0.08% 387
2021
Q1 		$458K Sell
18,171
-11,676
-39% -$228K 0.07% 386
2020
Q4 		$193K Buy
+29,847
New +$126K 0.03% 564

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Quantitative Systematic Strategies's ACRS Position: Q3 2021 in Review

Quantitative Systematic Strategies sold out of Aclaris Therapeutics (ACRS) in Q3 2021, closing a stake of 13,658 shares — an estimated $240K sold.

Quantitative Systematic Strategies first reported a position in ACRS in Q4 2020 and held it in 3 quarters. The position peaked at $458K in Q1 2021. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

  • Quantitative Systematic Strategies reported no remaining Aclaris Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 13,658 Aclaris Therapeutics shares in Q3 2021, an estimated $240K.
  • Quantitative Systematic Strategies first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 3 quarters.
  • Quantitative Systematic Strategies's Aclaris Therapeutics position peaked at $458K in Q1 2021.
  • 126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2021, filed 16 Nov 2021.